Last week, Oxford GlycoSciences management spurned a takeover bid by UK biotech Celltech, signaling that the company’s merger with Cambridge Antibody Technology announced Jan. 23 is more likely to go forward.
Last week, Oxford GlycoSciences management spurned a takeover bid by UK biotech Celltech, signaling that the company’s merger with Cambridge Antibody Technology announced Jan. 23 is more likely to go forward.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.